For the year ending 2025-12-31, BMYMP had -$129M decrease in cash & cash equivalents over the period. $12,845M in free cash flow.
| Cash Flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Net earnings/(loss) | 7,055 | -8,933 | 8,040 | 6,345 |
| Depreciation and amortization, net | 4,011 | 9,600 | 9,760 | 10,276 |
| Deferred income taxes | -965 | -2,089 | -3,288 | -2,738 |
| Stock-based compensation | 553 | 507 | 518 | 457 |
| Impairment charges | 1,098 | 2,963 | 255 | 179 |
| Divestiture gains and royalties | 1,165 | 1,119 | 884 | 1,063 |
| Acquired iprd | 3,721 | 13,373 | 913 | 815 |
| Equity investment (gains)/losses, net | 280 | 16 | -160 | -801 |
| Contingent consideration fair value adjustments | 351 | - | -8 | -9 |
| Other adjustments | -232 | -94 | -308 | -232 |
| Receivables | 295 | -264 | 995 | 663 |
| Inventories | 184 | 486 | 751 | 69 |
| Accounts payable | -2 | 184 | 198 | 109 |
| Rebates and discounts | -441 | 1,484 | 904 | 427 |
| Income taxes payable | -4 | -1,260 | -603 | -1,423 |
| Other | -471 | -624 | 667 | 610 |
| Net cash provided by operating activities | 14,156 | 15,190 | 13,860 | 13,066 |
| Sale and maturities of marketable debt securities | 1,975 | 1,122 | 733 | 6,411 |
| Purchase of marketable debt securities | 2,000 | 769 | 1,774 | 3,592 |
| Proceeds from sales of equity investment securities | - | - | - | 218 |
| Proceeds from sales of equity investments | 77 | 265 | 215 | - |
| Capital expenditures | 1,311 | 1,248 | 1,209 | 1,118 |
| Divestiture and other proceeds | 1,071 | 1,099 | 909 | 1,305 |
| Acquisition and other payments, net of cash acquired | 3,944 | 21,821 | 1,169 | 4,286 |
| Net cash provided by/(used in) investing activities | -4,132 | -21,352 | -2,295 | -1,062 |
| Proceeds from issuance of short-term debt obligations | 0 | 2,987 | - | - |
| Repayments of short-term debt obligations | 0 | 3,000 | - | - |
| Short-term debt obligations, net | - | - | -120 | 194 |
| Other short-term financing obligations, net | 25 | 99 | - | - |
| Proceeds from issuance of long-term debt | 5,740 | 12,883 | 4,455 | 5,926 |
| Repayments of long-term debt | 10,940 | 2,873 | 3,879 | 11,431 |
| Repurchase of common stock | 0 | 0 | 5,155 | 8,001 |
| Dividends | 5,045 | 4,863 | 4,744 | 4,634 |
| Stock option proceeds and other, net | -128 | -106 | 27 | 984 |
| Net cash provided by/(used in) financing activities | -10,348 | 5,127 | -9,416 | -16,962 |
| Effect of exchange rates on cash, cash equivalents and restricted cash | 195 | -137 | 45 | -33 |
| Increase/(decrease) in cash, cash equivalents and restricted cash | -129 | -1,172 | 2,194 | -4,991 |
| Cash and cash equivalents at beginning of period | 10,347 | 11,519 | 9,325 | 14,316 |
| Cash and cash equivalents at end of period | 10,218 | 10,347 | 11,519 | 9,325 |
BRISTOL MYERS SQUIBB CO (BMYMP)
BRISTOL MYERS SQUIBB CO (BMYMP)